Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Danielle Phares

Nurse Practitioner, Family Ft Lauderdale, FL Nurse Practitioner

NPI 1659785616 CMS profile 10947284

4750 N Federal Hwy Ste 302, Ft Lauderdale, FL 33308

Open in the dashboard

General payments

$712,872

877 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Danielle Phares of Ft Lauderdale, FL is reported in the CMS Open Payments database as having received $712,872 across 877 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $167,503 212
2024 General $166,227 202
2023 General $176,926 191
2022 General $110,895 140
2021 General $91,320 132

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Danielle Phares
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Danielle Phares were reported at $167,503. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Danielle Phares Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $91,320 $124 $35–$379 $132
2022 $110,895 $141 $44–$430 $149
2023 $176,926 $154 $49–$476 $160
2024 $166,227 $165 $51–$504 $164
2025 $167,503 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $510,609 602 payments
  2. Allergan Inc. $202,188 270 payments
  3. Galderma Laboratories, L.P. $45 3 payments
  4. AstraZeneca Pharmaceuticals LP $17 1 payment
  5. Ironshore Pharmaceuticals Inc. $14 1 payment

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $600,586 255 payments
  2. Travel and Lodging $72,391 304 payments
  3. Consulting Fee $21,817 13 payments
  4. Food and Beverage $18,061 303 payments
  5. Education $17 2 payments
Products named General payments · program years 2021–2025
  1. BOTOX Facial Aesthetics $358,063 436 payments
  2. KYBELLA $2,175 2 payments
  3. BOTOX Botox Therapeutic $17 1 payment
  4. FARXIGA $17 1 payment
  5. DYSPORT $15 1 payment
  6. JORNAY PM $14 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

877 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record